KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 95 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q2 2022. The put-call ratio across all filers is 0.44 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $320,668 | +9.2% | 18,461 | -11.5% | 0.20% | +12.1% |
Q2 2023 | $293,582 | +38.5% | 20,851 | +5.9% | 0.17% | +48.7% |
Q1 2023 | $211,929 | -26.9% | 19,696 | +1.8% | 0.12% | -22.5% |
Q4 2022 | $289,788 | -20.6% | 19,345 | -31.9% | 0.15% | +3.4% |
Q3 2022 | $365,000 | +34.7% | 28,407 | +1.5% | 0.15% | +46.0% |
Q2 2022 | $271,000 | -9.1% | 27,992 | -6.8% | 0.10% | -24.8% |
Q1 2022 | $298,000 | -15.6% | 30,021 | 0.0% | 0.13% | 0.0% |
Q4 2021 | $353,000 | +3.2% | 30,021 | +0.0% | 0.13% | -11.3% |
Q3 2021 | $342,000 | -25.0% | 30,009 | -8.4% | 0.15% | -20.2% |
Q2 2021 | $456,000 | +60.0% | 32,762 | +112.5% | 0.19% | +56.7% |
Q1 2021 | $285,000 | +6.3% | 15,414 | +1.8% | 0.12% | +8.1% |
Q4 2020 | $268,000 | +22.4% | 15,148 | +5.8% | 0.11% | -3.5% |
Q3 2020 | $219,000 | -47.2% | 14,317 | -12.0% | 0.12% | -41.6% |
Q2 2020 | $415,000 | +95.8% | 16,274 | +38.3% | 0.20% | -56.3% |
Q1 2019 | $212,000 | -44.2% | 11,763 | -13.1% | 0.45% | +593.8% |
Q4 2018 | $380,000 | – | 13,536 | – | 0.06% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Spearhead Capital Advisors, LLC | 202,580 | $2,601,000 | 2.82% |
Lion Point Capital, LP | 480,000 | $5,140,000 | 1.13% |
HHLR ADVISORS, LTD. | 2,920,023 | $37,493,000 | 0.99% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $7,704,000 | 0.94% |
Rubric Capital Management LP | 1,446,107 | $18,568,000 | 0.94% |
AlphaCentric Advisors LLC | 43,000 | $552,000 | 0.57% |
RICE HALL JAMES & ASSOCIATES, LLC | 749,933 | $9,629,000 | 0.56% |
Parkman Healthcare Partners LLC | 126,192 | $1,620,000 | 0.46% |
Birchview Capital, LP | 30,000 | $385,000 | 0.27% |
Baker Brothers Advisors | 2,799,577 | $35,947,000 | 0.24% |